Christine Brown, Ph.D. (IMAGE)
Caption
Researchers from City of Hope have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. “The power of this platform is its flexibility,” said Dr. Christine Brown, City of Hope’s Heritage Provider Network Professor in Immunotherapy. “Instead of hardwiring every function into a CAR T cell, we can use protein-adaptor plug-ins to add new capabilities as needed, improving their ability to overcome tumor heterogeneity and other barriers that limit CAR T therapy in solid tumors.”
Credit
City of Hope
Usage Restrictions
Please use credit
License
Original content